{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:44:17Z","timestamp":1792619057577,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite advancements in treatment options for metastatic urothelial carcinoma (mUC), therapeutic choices remain limited for patients with disease refractory to platinum-based chemotherapy (PBC) and immune checkpoint inhibitors (ICIs). Enfortumab vedotin (EV) has demonstrated significant efficacy in later lines of therapy for mUC; however, its organ-specific responses remain uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a retrospective study of 69 patients with mUC who received EV following treatment with PBC and ICIs. Efficacy was assessed using Response Evaluation Criteria in Solid Tumors, with organ-specific response rates (OSRR) and organ-specific disease control rates (OSCR) calculated across different metastatic sites. Multivariate Cox regression analysis was performed to identify independent predictors of disease progression and survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median progression-free survival (PFS) was 8.3\u00a0months, whereas the median overall survival (OS) was 18.0\u00a0months. The objective response rate (ORR) was 53.6%, and the disease control rate (DCR) was 82.6%. OSCR was \u226570% across all metastatic sites, confirming the broad efficacy of EV. Liver metastases exhibited the highest OSRR at 66.7%, whereas bone metastases had the lowest OSRR at 12.5%. Tumor burden reduction was significantly lower in bone metastases compared to other metastatic sites. Disease progression was predominantly observed at target lesions, with a median time to progression of 3\u00a0months. Eastern Cooperative Oncology Group performance status and serum C-reactive protein levels were identified as significant independent predictors of PFS and OS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>EV exhibited favorable organ-specific tumor responses in mUC, with particularly high efficacy against liver metastasis. However, response rates were lower in bone metastases. No significant differences in organ-specific overall survival were observed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf060","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:01:05Z","timestamp":1744135265000},"page":"807-815","source":"Crossref","is-referenced-by-count":7,"title":["Organ-specific tumor response to enfortumab vedotin in metastatic urothelial carcinoma: a multicenter retrospective study"],"prefix":"10.1093","volume":"55","author":[{"given":"Fumihiko","family":"Urabe","sequence":"first","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei the 3rd Hospital , 4-11-1, Izumihoncho, Komae-shi, Tokyo, 201-8601 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Taneda","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashita, Kashiwa-shi, Chiba ,","place":["277-8567, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashita, Kashiwa-shi, Chiba ,","place":["277-8567, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuki","family":"Muramoto","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei the 3rd Hospital , 4-11-1, Izumihoncho, Komae-shi, Tokyo, 201-8601 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei the 3rd Hospital , 4-11-1, Izumihoncho, Komae-shi, Tokyo, 201-8601 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Katsushika Medical Center , 6-41-2, Aoto, Katsushika-ku, Tokyo ,","place":["125-8506, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Nerima Hikarigaoka Hospital , 2-5-1, Hikarigaoka, Nerima-ku, Tokyo, 179-0072 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Nakazono","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Kameda Medical Center , 929, Higashicho, Kamogawa-shi, Chiba, 296-8602 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimu","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Tokyo Metropolitan Hiroo Hospital , 2-34-10, Ebisu, Shibuya-ku, Tokyo ,","place":["150-0013, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Fuji City General Hospital , 50, Takashimacho, Fuji-shi, Shizuoka, 417-8567 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashita, Kashiwa-shi, Chiba ,","place":["277-8567, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Kayano","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, SUBARU Health Insurance Society Ota Memorial Hospital , 455-1, Ooshimacho, Oota-shi, Gunma, 373-8585 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahito","family":"Atsuta","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashita, Kashiwa-shi, Chiba ,","place":["277-8567, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Aikawa","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Saitama Northern Medical Center , 1-851, Miyaharacho, Kita-ku, Saitama, 331-8625 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Katsushika Medical Center , 6-41-2, Aoto, Katsushika-ku, Tokyo ,","place":["125-8506, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaya","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo ,","place":["105-8461, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]},{"name":"Department of Urology, Jikei Kashiwa Hospital , 163-1, Kashiwashita, Kashiwa-shi, Chiba ,","place":["277-8567, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Urology, The Jikei University School of Medicine , 3-25-8, Nishishimbashi, Minato-ku, Tokyo, 105-8461 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"JIKEI-YAYOI Collaborative Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2025070702415426700_ref1","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/iju.13376","article-title":"Epidemiology of urothelial carcinoma","volume":"24","author":"Miyazaki","year":"2017","journal-title":"Int J Urol"},{"key":"2025070702415426700_ref2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1186\/s12885-023-10930-2","article-title":"Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance","volume":"23","author":"Nishiyama","year":"2023","journal-title":"BMC Cancer"},{"key":"2025070702415426700_ref3","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025070702415426700_ref4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2025070702415426700_ref5","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2025070702415426700_ref6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2025070702415426700_ref7","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/cam4.5165","article-title":"Japanese subgroup analysis of EV-301: an open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma","volume":"12","author":"Matsubara","year":"2023","journal-title":"Cancer Med"},{"key":"2025070702415426700_ref8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00432-024-05717-2","article-title":"Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan","volume":"150","author":"Hirasawa","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025070702415426700_ref9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/iju.15437","article-title":"Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data","volume":"31","author":"Uemura","year":"2024","journal-title":"Int J Urol"},{"key":"2025070702415426700_ref10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/iju.15411","article-title":"Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan","volume":"31","author":"Kita","year":"2024","journal-title":"Int J Urol"},{"key":"2025070702415426700_ref11","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/cancers16152648","article-title":"Oncologic outcomes of patients with immune checkpoint inhibitor resistant urothelial carcinoma treated with Enfortumab Vedotin and the impact of neutrophil-to-lymphocyte ratio and Dysgeusia on overall survival: a retrospective Multicenter cohort study in Japan","volume":"16","author":"Nakane","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025070702415426700_ref12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025070702415426700_ref13","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15300","article-title":"Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: a multicenter propensity score-matched study","volume":"30","author":"Taguchi","year":"2023","journal-title":"Int J Urol"},{"key":"2025070702415426700_ref14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/jjco\/hyad170","article-title":"Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort","volume":"54","author":"Miyake","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2025070702415426700_ref15","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2147\/OTT.S299724","article-title":"Organ-specific tumor response to Pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy","volume":"14","author":"Furubayashi","year":"2021","journal-title":"Onco Targets Ther"},{"key":"2025070702415426700_ref16","doi-asserted-by":"publisher","first-page":"312","DOI":"10.21037\/tlcr-23-83","article-title":"Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer-a retrospective cohort study","volume":"12","author":"Wang","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2025070702415426700_ref17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"2025070702415426700_ref18","doi-asserted-by":"publisher","first-page":"102148","DOI":"10.1016\/j.clgc.2024.102148","article-title":"Organ-specific tumor response to Enfortumab Vedotin for metastatic urothelial carcinoma: a Multicenter retrospective study","volume":"22","author":"Minato","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"2025070702415426700_ref19","doi-asserted-by":"publisher","first-page":"1493922","DOI":"10.3389\/fonc.2024.1493922","article-title":"Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs","volume":"14","author":"Ikarashi","year":"2024","journal-title":"Front Oncol"},{"key":"2025070702415426700_ref20","doi-asserted-by":"publisher","first-page":"495.e9","DOI":"10.1016\/j.urolonc.2015.07.001","article-title":"The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy","volume":"33","author":"Hsieh","year":"2015","journal-title":"Urol Oncol"},{"key":"2025070702415426700_ref21","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1007\/s00262-022-03204-6","article-title":"Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis","volume":"71","author":"Yoshida","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2025070702415426700_ref22","doi-asserted-by":"crossref","first-page":"e440","DOI":"10.1016\/j.clgc.2022.06.001","article-title":"Association between sites of metastasis and outcomes with immune checkpoint inhibitors in advanced urothelial carcinoma","volume":"20","author":"Makrakis","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2025070702415426700_ref23","doi-asserted-by":"crossref","first-page":"17588359221094879","DOI":"10.1177\/17588359221094879","article-title":"The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy","volume":"14","author":"Alqaisi","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2025070702415426700_ref24","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/iju.15640","article-title":"Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: a landmark analysis","volume":"32","author":"Taguchi","year":"2024","journal-title":"Int J Urol"},{"key":"2025070702415426700_ref25","doi-asserted-by":"crossref","first-page":"107302","DOI":"10.1016\/j.phrs.2024.107302","article-title":"Relationship between clonal evolution and drug resistance in bladder cancer: a genomic research review","volume":"206","author":"Tuo","year":"2024","journal-title":"Pharmacol Res"},{"key":"2025070702415426700_ref26","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025070702415426700_ref27","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with Enfortumab Vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/7\/807\/62889050\/hyaf060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/7\/807\/62889050\/hyaf060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T06:42:00Z","timestamp":1751870520000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/7\/807\/8108226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4,8]]},"published-print":{"date-parts":[[2025,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf060","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,4,8]]}}}